Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 8;384(14):1372-1374.
doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer  1 , Komal Srivastava  1 , Hala Alshammary  1 , Angela A Amoako  1 , Mahmoud H Awawda  1 , Katherine F Beach  1 , Maria C Bermúdez-González  1 , Dominika A Bielak  1 , Juan M Carreño  1 , Rachel L Chernet  1 , Lily Q Eaker  1 , Emily D Ferreri  1 , Daniel L Floda  1 , Charles R Gleason  1 , Joshua Z Hamburger  1 , Kaijun Jiang  1 , Giulio Kleiner  1 , Denise Jurczyszak  1 , Julia C Matthews  1 , Wanni A Mendez  1 , Ismail Nabeel  1 , Lubbertus C F Mulder  1 , Ariel J Raskin  1 , Kayla T Russo  1 , Ashley-Beathrese T Salimbangon  1 , Miti Saksena  1 , Amber S Shin  1 , Gagandeep Singh  1 , Levy A Sominsky  1 , Daniel Stadlbauer  1 , Ania Wajnberg  1 , Viviana Simon  1
Affiliations

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Immunogenicity and Reactogenicity of SARS-CoV-2 RNA Vaccines.
Panel A shows the quantitative SARS-CoV-2 spike antibody titers (assessed by means of enzyme-linked immunosorbent assay and expressed as area under the curve [AUC]) for 110 participants. Some participants with preexisting immunity had antibody titers below detection (AUC of 1) at the time point before vaccination. Geometric means with 95% confidence intervals (not adjusted for multiple testing) are shown. Panel B shows the relative frequency of vaccine-associated side effects after the first vaccine dose (230 participants). The local side effects occurred with similar frequency among participants with preexisting immunity and among those without preexisting immunity, whereas the systemic symptoms were more common among participants with preexisting immunity. The bars represent the relative frequency of each symptom, and the numbers at the top of the graph represent the absolute numbers for a given symptom, with a given participant possibly having more than one symptom.
See this image and copyright information in PMC

References

    1. Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-527. - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. - PMC - PubMed
    1. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol 2020;57(1):e100-e100. - PMC - PubMed
    1. Stadlbauer D, Tan J, Jiang K, et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature 2021;590:146-150. - PubMed